JAMIE JONES: Open Payments
NPI 1114353117 · COPPERAS COVE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 46 payments from 19 companies in 2025. Trend: 2023 $1,150 · 2024 $983 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $195 |
| Novo Nordisk Inc | 6 | $104 |
| Exact Sciences Corporation | 5 | $96 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $94 |
| GlaxoSmithKline, LLC. | 3 | $64 |
| Lilly USA, LLC | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Amgen Inc. | 2 | $32 |
Products named: QULIPTA, Cologuard Collection Kit, Kerendia, Ozempic, VRAYLAR, TRELEGY ELLIPTA, REXULTI, MOUNJARO.
Industry payments across TX — which companies pay providers there.
